DAFLNet: Dual Asymmetric Feature Learning Network for COVID-19 Disease Diagnosis in X-Rays

Abstract

COVID-19 has become the largest public health event worldwide since its outbreak, and early detection is a prerequisite for effective treatment. Chest X-ray images have become an important basis for screening and monitoring the disease, and deep learning has shown great potential for this task. Many studies have proposed deep learning methods for automated diagnosis of COVID-19. Although these methods have achieved excellent performance in terms of detection, most have been evaluated using limited datasets and typically use a single deep learning network to extract features. To this end, the dual asymmetric feature learning network (DAFLNet) is proposed, which is divided into two modules, DAFFM and WDFM. DAFFM mainly comprises the backbone networks EfficientNetV2 and DenseNet for feature fusion. WDFM is mainly for weighted decision-level fusion and features a new pretrained network selection algorithm (PNSA) for determination of the optimal weights. Experiments on a large dataset were conducted using two schemes, DAFLNet-1 and DAFLNet-2, and both schemes outperformed eight state-of-the-art classification techniques in terms of classification performance. DAFLNet-1 achieved an average accuracy of up to 98.56% for the triple classification of COVID-19, pneumonia, and healthy images.

Transcription Factor E2F8 Promotes Cisplatin Resistance in Hepatocellular Carcinoma by Regulating DNA Damage via NUSAP1

“…Currently, there are diverse forms of therapeutic regimens for liver cancer such as hepatectomy, chemotherapy, immunotherapy, radiofrequency ablation, or alcohol ablation, 2 as well as liver transplantation. [3][4][5][6] Though the aforementioned treatment options can improve patient's survival, chemotherapy remains the optimal method of clinical care. At present, platinumbased combined chemotherapy is one of the important means of treatment for patients with advanced HCC, among which cisplatin is an effective and widely used first-line drug.…”